Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Delanzomib |
Proteasome Inhibitor | Hematologic (Multiple Myeloma) | ||
|
Molecule
Delanzomib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
||||
Denileukin Diftitox |
IL-2 / Diphtheria Toxin Fusion Protein, anti-CD25 | Hematologic (Lymphoma) | ||
|
Molecule
Denileukin Diftitox
Therapeutic Category
Immunotherapy (Cytokine)
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
IL-2 / Diphtheria Toxin Fusion Protein, anti-CD25 |
||||
Depatuxizumab Mafodotin |
ADC | Solid Tumour | ||
|
Molecule
Depatuxizumab Mafodotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Derazantinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Derazantinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Dinaciclib |
CDK Inhibitor | Solid Tumour | ||
|
Molecule
Dinaciclib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
||||
Dinutuximab |
PDGFR / GD2 Targeting Agent | Solid Tumour (Sarcoma/Neuroblastoma) | ||
|
Molecule
Dinutuximab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
||||
Disitamab Vedotin |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Disitamab Vedotin
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
Divarasib |
RET / MET / KRAS / IDH Inhibitor | Solid Tumour | ||
|
Molecule
Divarasib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
||||
Donafenib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Donafenib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Dostarlimab |
Anti-PD-1 mAb | Both (Solid & Hematologic) | ||
|
Molecule
Dostarlimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
||||
Dovitinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Dovitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Duvelisib |
PI3K Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Duvelisib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
||||
DelanzomibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
|
Denileukin DiftitoxImmunotherapy (Cytokine) |
|
|
Therapeutic Category
Immunotherapy (Cytokine)
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
IL-2 / Diphtheria Toxin Fusion Protein, anti-CD25 |
|
Depatuxizumab MafodotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
DerazantinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
DinaciclibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
|
DinutuximabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
|
Disitamab VedotinTargeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|
DivarasibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
|
DonafenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
DostarlimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
|
DovitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
DuvelisibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
|